What is the recommended management for a patient with Gleason 3 + 4 (score 7) prostate cancer and a PSA of 4 ng/mL?

Management of Gleason 3+4 (Grade Group 2) Prostate Cancer with PSA 4 ng/mL

For a patient with Gleason 3+4 prostate cancer and PSA 4 ng/mL, active surveillance is a reasonable option if disease volume is low (<10% pattern 4, ≤3 positive cores, <50% involvement per core, cT1c-T2a), though approximately 21-30% risk of harboring higher-grade or higher-stage disease exists even in favorable cases. 1, 2, 3

Risk Stratification

This patient has NCCN favorable intermediate-risk disease based on:

• Gleason 3+4 (ISUP Grade Group 2) 1
• PSA <10 ng/mL 1
• Presumed clinical stage ≤T2a 1

The 2024 EAU guidelines specifically state that active surveillance can be offered to selected patients with ISUP grade group 2 disease meeting specific criteria: <10% pattern 4, PSA <10 ng/ml, cT2a or lower, low disease extent on imaging, and low biopsy tumor extent (≤3 positive cores with <50% cancer involvement per core) 1.

Critical Decision Points

MRI Assessment is Essential

• Perform multiparametric MRI before confirmatory biopsy if not already done 1
• MRI helps assess true disease volume and exclude higher-risk features 1
• Take both targeted biopsy of any PI-RADS ≥3 lesions and systematic biopsy 1

Exclude High-Risk Histology

Patients with cribriform or intraductal histology must be excluded from active surveillance 1. These features dramatically increase risk regardless of Gleason score.

Treatment Options

Active Surveillance (Preferred for Favorable Cases)

Active surveillance is appropriate if ALL of the following are met 1:

• <10% Gleason pattern 4 on biopsy
• ≤3 positive cores
• <50% cancer involvement per core
• No cribriform or intraductal patterns
• Low volume on MRI
• Life expectancy >10 years

However, recognize the limitations: Even with PSA ≤4.0 ng/mL and <12.5% positive cores, 21.7% of patients harbor more advanced disease at surgery 3. With your patient's PSA of 4 ng/mL, if percentage of positive cores is low (<12.5%), the risk remains around 22%, but this increases substantially with higher core involvement 3.

Definitive Treatment Options

If active surveillance criteria are not met or patient preference favors treatment 1:

Radical Prostatectomy:

• Offer to patients with life expectancy >10 years 1
• Can safely be delayed 3 months if needed 1
• Nerve-sparing appropriate if low risk of extracapsular extension 1

Radiation Therapy:

• IMRT/VMAT with IGRT: 76-78 Gy conventional or moderate hypofractionation (60 Gy/20 fractions or 70 Gy/28 fractions) 1
• Combine with short-term ADT (4-6 months) for intermediate-risk disease 1
• Alternative: Ultrahypofractionated IMRT/IGRT (36.25-40 Gy in 5 fractions or 42.7 Gy in 7 fractions) 1
• LDR brachytherapy appropriate for favorable intermediate-risk with good urinary function 1

Surveillance Protocol if Chosen

• Repeat biopsies at least once every 3 years for 10 years 1
• Do not progress to treatment without repeat biopsy if PSA progression, DRE changes, or MRI changes occur 1
• Reclassify if repeat biopsies show >3 positive cores or >50% involvement per core 1

Common Pitfalls

Underestimating disease burden: 30.3% of Gleason 3+4 favorable intermediate-risk patients are upgraded to ≥Gleason 4+3 or upstaged to ≥pT3 at surgery 3. Clinical parameters alone (PSA, stage, core involvement) have limited predictive accuracy 2.

Age considerations: Older patients (≥67 years) have 1.46 times higher odds of harboring more advanced disease compared to younger patients (≤55 years) 3.

Pattern 4 percentage matters: The proportion of pattern 4 is critical—ensure pathology report specifies this 1.